Urine-Based Molecular Testing Service

University Hospitals of North Midlands NHS Trust

Value
Not stated
Published
10 Sept 2026
Deadline
Not stated
Procedure
Not stated
Location
Stoke on Trent, UKG, ST4 6QG, United Kingdom
Notice reference
086052-2026

Requirements summary

University Hospitals of North Midlands NHS Trust is procuring a urine-based molecular testing service to triage eligible non-visible haematuria patients as a non-invasive alternative to routine diagnostic cystoscopy for an agreed low-risk cohort. The provider must handle home sample collection and return logistics, laboratory analysis against a defined bladder cancer-associated molecular panel, and secure reporting of results as negative/low-risk or positive/high-risk. The amended estimated contract duration is 1 November 2026 to 31 March 2027.

Key requirements

  • Provider of a urine-based molecular testing service for eligible non-visible haematuria patients
  • Home urine sample collection, sample kits, return logistics and robust chain-of-custody
  • Laboratory analysis against a defined bladder cancer-associated molecular panel with documented quality controls
  • Results available within 7 calendar days of sample receipt, with at least 90% compliance; kits issued within 2 working days; non-conforming samples notified within 1 working day
  • Service operates within UHNM clinical decision rules, including escalation routes and safety-netting for negative results
  • Monthly KPI dashboard, quarterly clinical governance pack and support for pathway data collection
  • Mobilisation within 4 weeks, followed by a 3-month pilot and business-as-usual delivery from month 4 where agreed
Urine-Based Molecular Testing Service — University Hosp… | ProposAI